Outsourced Pharma Chief Editor Louis Garguilo has interviewed Ali Pashazadeh, Treehill Partners CEO, to help think through the evolving U.S. policies and tariff turbulance as they relate to the outsourcing of development and manufacturing processes and functions in the pharmaceutical industry.
- When it comes to candidate development and manufacturing supply chains, players either evolve or will get extinct.
- Future state of the economy and financial markets are not something the markets as a whole or individual investors will ‘get right’ with sufficient degree of confidence – which needs to be factored into strategic decisions.
- The vast majority of companies will however find a reason to keep doing exactly what they were doing earlier, putting them at significant risk of inviability.
Read the full article on Outsourced Pharma: